1. Paroxetine treatment, following behavioral suppression of PTSD-like symptoms in mice, prevents relapse by activating the infralimbic cortex 
Yassine Bentefour, Youness Rakibi, Mohamed Bennis, Saadia Ba-M’hamed, René Garcia 
European Neuropsychopharmacology 
Volume 26, Issue 2, Pages (February 2016)
DOI: /j.euroneuro
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

2. Figure 1
Avoidance behavior in different conditions. (a) Mean (±SEM) step-through latency, during training session, before the 1.5mA foot-shock experience (day 1) and during each subsequent test sessions (days 2, 14 and 30) in the three groups (Control, Ext and Ext+FSP). (b) Mean (±SEM) step-through latency during extinction sessions (days 31–35). (c) Mean (±SEM step-through latency before (day 43: during relapse provocation session) and after (days 44 and 45) the foot-shock priming (FSP: 0.3mA) exposure. ***, ** and *: significantly different from the Control group, p< (or p<0.001), p<0.01 and p<0.05, respectively; ###, ## and #: significantly different from the Ext group, p<0.0001, p<0.01 and p<0.05, respectively.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

3. Figure 2
Freezing behavior in different conditions. Mean (±SEM) freezing, expressed by the three groups (Control, Ext and Ext+FSP) on day 47 (4 days after the foot-shock priming exposure), during the first 60s in the environment of neutral cue trials (a), during neutral cue trials (b) and during the 60s of re-exposure to the conditioning context (c). ***: significantly different from the Control group, p<0.0001; ### and ##: significantly different from the Ext group, p< and p<0.01, respectively.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

4. Figure 3
Anxiety-like behavior in the elevated plus maze (EPM). (a) Mean (±SEM) number of entries in the open arms displayed by the three groups of mice (Control, Ext, and Ext+FSP) on day 48 (5 days after the foot-shock priming exposure). (b) Mean (±SEM) time spent in the open arms. (c) Mean (±SEM) distance moved in the EPM. *** and **: significantly different from the Control group, p< and p<0.01, respectively; ### and #: significantly different from the Ext group, p< and p<0.05, respectively.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

5. Figure 4
Effect of paroxetine (PRX) on avoidance. (a) Mean (±SEM) step-through latency before the 1.5mA foot-shock experience (day 1) and during each subsequent retention test (days 2, 14 and 30) in the two groups (Ext+Veh and Ext+PRX) and the Control group from Experiment 1. (b) Mean (±SEM) step-through latency during extinction training (days 31–35). (c) Mean (±SEM) step-through latency before (day 43) and after (days 44 and 45) the foot-shock priming (FSP: 0.3mA) exposure. ***, ** and *: significantly different from the Control group, p< (or p<0.001), p<0.01 and p<0.05, respectively; ### and #: significantly different from the Ext group, p< (or p<0.001) and p<0.05, respectively.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

6. Figure 5
Effects of paroxetine (PRX) on freezing behavior. Mean (±SEM) freezing, expressed by the two groups (Ext+Veh and Ext+PRX; the Control being from Experiment 1) on day 47 (4 days after the foot-shock priming exposure), during the first 60s in the environment of neutral cue trials (a), during neutral cue trials (b) and during the 60s of re-exposure to the conditioning context (c). ***: significantly different from the Control group, p< (or p<0.001); ###: significantly different from the Ext+Veh group, p< (or p<0.001).
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

7. Figure 6
Effect of paroxetine on anxiety-like behavior. (a) Mean (±SEM) number of entries in the open arms of the elevated plus maze (EPM) displayed by the two groups (Ext+Veh and Ext+PRX; the Control group being from Experiment 1) on day 48 (5 days after the foot-shock priming exposure). (b) Mean (±SEM) time spent in the open arms. (c) Mean (±SEM) distance moved in the EPM. *** and **: significantly different from the Control group, p<0.001 and p<0.01, respectively; ### and ##: significantly different from the Ext+Veh group, p<0.001 and p<0.01, respectively.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

8. Figure 7
Representative photomicrographs of Fos immunohistochemical staining in two distinct areas of the medial prefrontal cortex (the prelimbic area, PrL, and the infralimbic area, IL) of a mouse from the Ext+Veh group and a mouse from the Ext+PRX group. M2, secondary motor cortex; Cg1, cingulate cortex, area 1; CPu, caudate putamen.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

9. Figure 8
Number of c-Fos positive cells in two areas of the medial prefrontal cortex: the prelimbic (PrL) and infralimbic (IL) areas. (a) Mean (±SEM) number of c-Fos positive cells in PrL of each of the three groups (Control, Ext+Veh and Ext+PRX). (b) Mean (±SEM) number of c-Fos positive cells in IL of each group. *: significantly different from the Control group, p<0.05; #: significantly different from the Ext+Veh group, p<0.05.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

10. Fig. 9
Cannula placements with a representative angled placement in the medial prefrontal cortex (right).
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions

11. Figure 10
Effect of tetrodotoxin (TTX). (a) Mean (±SEM) step-through latency before the 1.5mA foot-shock experience (day 1) and during each subsequent retention test (days 2, 14 and 30) in the two groups (Veh+TTX+veh and PRX+veh+TTX). (b) Mean (±SEM) step-through latency during extinction training (days 31–35). (c) Mean (±SEM) step-through latency before (day 43) and after (days 44 and 45) the foot-shock priming (FSP: 0.3mA) exposure. TTX was infused into the medial prefrontal cortex before the relapse test on day 44 (Veh+TTX+veh group) or on day 45 (PRX+veh+TTX). ***: significantly different from Veh+TTX+veh mice, p<0.001.
European Neuropsychopharmacology  , DOI: ( /j.euroneuro )
Copyright © 2015 Elsevier B.V. and ECNP Terms and Conditions